In the first article by Jean-Sabastian Hulot and colleagues, the authors review a list of parameters that need to be considered for launching clinical trials of PSC-derived CMs \[[@CR1]\]. These include the need for good manufacturing practice clinical grade cells, immunological consideration, an efficient cardiac differentiation protocol, purification of chamber-specific derived PSC-CMs, and optimized delivery methods for improved retention, survival and engraftment of the transplanted cells or tissues. The advantages and limitations of using large animal models such as porcine and non-human primates for pre-clinical testing are also discussed.

Hung-Fat Tse and Song-Yan Liao review the pros and cons of using multi-potent (adult) stem cells and PSCs for heart regeneration \[[@CR2]\]. Specifically, human skeletal muscle myoblasts, bone marrow-derived cells, endothelial progenitor cells, mesenchymal stem cells and cardiac resident stem cells are compared with human embryonic stem cells and iPSCs. In brief, while adult stem cells represent a conceptually attractive autologous option, their ability to regenerate the myocardium appears to be limited.

While any stem cell-based clinical translations are going to take time because of defined regulatory processes that need to be followed, recent technological advances have enabled PSC-CMs to immediately serve as excellent *in vitro* diagnostic tools for drug discovery, toxicity screening and disease modeling. Arun Sharma, Sean Wu and Joseph Wu review the use of iPSCs for disease modeling and drug screening \[[@CR3]\]. In their article, the LEOPARD syndrome, long QT syndromes, catecholaminergic polymorphic ventricular tachycardia, hereditary dilated and hypertrophic cardiomyopathy and arrhythmogenic right ventricular dysplasia/cardiomyopathy, which have been modeled using iPSCs, are given as specific examples.

Despite the promises of iPSC technology, however, there are hurdles that need to be overcome. A well-recognized roadblock has been the immaturity of PSC-CMs. The review article by Wendy Keung, Kenneth Boheler and Ronald Li summarizes the immature structural, electrophysiological, calcium-handling, bioenergetic and metabolic properties of PSC-CMs as well as our current understanding of their underlying molecular bases \[[@CR4]\]. Based on this knowledge, *in vitro* approaches that focus on such developmental cues as neurohormones, epigenetic, micro-RNA and transcriptomic cues, and non-cell autonomous microenvironmental factors (for example, electrical and mechanical stimuli) have been accordingly developed to recreate niche environments for driving maturation. Along this line, Ken Boheler and colleagues \[[@CR5]\] describe in their article how various physical parameters such as bio-scaffold, cell alignment and three-dimensional environments can contribute to the maturation and functionality of PSC-CMs.

Pragmatically, the use of PSC-CMs for *in vitro* diagnostics and/or cell-based therapies can be realized only if these cells can be mass produced with high standards of quality control. Steve Oh and colleagues \[[@CR6]\] review considerations in designing bioreactor systems for scalable production of human PSC-CMs. Two-dimensional monolayer cell culture, cell-aggregate and microcarrier are compared in the context of platform selection, bioprocess parameters, medium development, downstream processing and parameters that meet current good manufacturing practice standards.

Although human PSC-based heart regeneration is a new concept and discipline with a relatively short history of about a decade, significant scientific and technical advances are being made at remarkably rapid rates, ushering in a new era of cardiovascular bio-engineering and regenerative medicine. It is with every optimism that the knowledge gained during the process not only enables a better basic understanding of the human heart but will also translate into tangible healthcare benefits in the not too distant future.

Note {#Sec1}
====

This article is part of a thematic series on *Cardiovascular regeneration* edited by Ronald Li. Other articles in the series can be found online at <http://stemcellres.com/series/cardiovascular>.
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